ClinicalTrialsFinder
RecruitingNot ApplicableNCT05934409

Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

Sponsor

Université de Sherbrooke

Enrollment

40 participants

Start Date

Nov 1, 2023

Study Type

INTERVENTIONAL

Summary

The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

  • Aged 18 to 65
  • BMI 35 kg/m2
  • Diagnosed T2D - according to Diabetes Canada diagnostics criteria.
  • Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.
  • Women with a negative serum pregnancy test.

Exclusion Criteria11

  • Treatment with an oral contraceptive;
  • Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects;
  • Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions;
  • Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension;
  • Smoking or consumption of more than 2 alcoholic beverages per day;
  • Any contraindication to MRI;
  • A Diabetes Remission (DiaRem) score >8 (low probability of T2D remission);
  • Having participated to a research study with exposure to radiation in the last two years before the start of the study;
  • Pregnant or breastfeeding women;
  • Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners.
  • Being allergic to eggs

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBariatric surgery

Laparoscopic Sleeve Gastrectomy

DRUGNicotinic Acid

Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.

Locations(1)

centre de recherche du CHUS

Sherbrooke, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05934409